Apr 12, 2021 4:30pm EDT Immunocore presents phase 3 data comparing tebentafusp with investigator’s choice in the clinical trial plenary session at the American Association for Cancer Research 2021 Annual Meeting
Mar 25, 2021 7:00am EDT Immunocore Provides Business Update and Reports Full Year 2020 Financial Results
Mar 10, 2021 7:00pm EST Immunocore Announces Upcoming Presentations at the American Association for Cancer Research (AACR) 2021 Annual Meeting
Feb 19, 2021 7:00am EST Immunocore’s tebentafusp granted Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma from FDA